In just a few years, CRISPR, the revolutionary gene editing technology, has become science’s “it” discipline, giving birth to a bitter patent dispute, billions in biotech investments, and an in-development primetime TV drama. But unlike the comparatively less buzzy pursuits of virology and animal husbandry, CRISPR has lacked one of academia’s unsexier badges of honor: a peer-reviewed journal to call its own.
That’s going to change come 2018 with the arrival of The CRISPR Journal, a bimonthly publication that seeks to chronicle every breakthrough, ethical debate, and legal quandary in the world of gene editing.
There are, from the Annals of Botany to the curiously named Zootaxa, a dizzying number of journals already, and the world of science can be forgiven for a little peer-reviewed fatigue, said Kevin Davies, the executive vice president at publisher Mary Ann Liebert who is leading the magazine’s launch. But CRISPR, with its potential to rewrite life itself, merits an addition to the crowded coffee tables of the world’s labs and libraries, Davies argues.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect